XML 39 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Summary of Significant Accounting Policies - Narrative (Details)
1 Months Ended 3 Months Ended
Jul. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
segment
shares
Jun. 30, 2020
USD ($)
Jul. 28, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of operating segments | segment   1    
Number of reporting segments | segment   1    
Cash, cash equivalents and marketable securities   $ 569,800,000    
Pfizer and Richter        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Decrease in contract liability from regulatory milestones achieved   $ 115,000,000.0    
Sumitomo Dainippon Pharma Co., Ltd. | Majority Shareholder        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of shares owned (in shares) | shares   48,641,181    
Ownership percentage   52.90%    
Sumitomo Dainippon Pharma Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan | Majority Shareholder        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Available borrowing capacity   $ 41,300,000    
Pfizer | Subsequent Event        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Decrease in contract liability from regulatory milestones achieved $ 100,000,000.0      
Outstanding payment from milestones achieved       $ 3,600,000,000
Richter        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Decrease in contract liability from regulatory milestones achieved     $ 33,300,000  
Richter | Subsequent Event        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Decrease in contract liability from regulatory milestones achieved $ 15,000,000.0      
Outstanding payment from milestones achieved       $ 122,500,000